Detail akcie Cytokinetics online

Business Summary: Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Cytokinetics, Inc. revenues increased from $1.6M to $19.4M. Net loss increased 28% to $206M. Revenues reflect Revenue Sales of Goods & Serv increase of 67% to $2.6M. Higher net loss reflects Cytokinetics segment loss increase of 18% to $183.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.36 to -$1.67.